21 Aug 2023 – We are thrilled to share that EyRIS has achieved a significant milestone by receiving TGA (Therapeutic Goods Administration) approval for the use of SELENA+ in Australia. This achievement underscores our commitment to detect retinal diseases and ultimately eliminate preventable blindness through early treatment on a global scale.
A pivotal aspect of this achievement is our strategic collaboration with Optometrist Warehouse, a subsidiary of the widely-known Chemist Warehouse group. This partnership harnesses strengths from two organisations to introduce innovations to derive positive healthcare outcomes.
SELENA+ is a Deep Learning System (DLS), a breakthrough machine learning technology that utilizes representation-learning methods with multiple levels of representation to process natural data in their raw form, recognizing the intricate structures in high-dimensional data. This revolutionary tech performs automated image analysis for eye diseases such as diabetic retinopathy with add-on modules for glaucoma and age-related macular degeneration. This tech has the potential to significantly decrease public health care costs while ensuring the highest standard of care.
Please direct all queries related to this article to Marketing at firstname.lastname@example.org
Comments are closed.